Cargando…

A CLDN1-Negative Phenotype Predicts Poor Prognosis in Triple-Negative Breast Cancer

INTRODUCTION: Triple-negative breast cancer (TNBC) is a heterogeneous disease with no definitive prognostic markers. As a major component of tight junctions, claudins (CLDNs) presumably play an important role in carcinogenesis and progression of breast cancer. This study was aimed at determining the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Fei, Ding, Xiaoyan, Fan, Ying, Ying, Jianming, Zheng, Shan, Lu, Ning, Xu, Binghe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231092/ https://www.ncbi.nlm.nih.gov/pubmed/25393310 http://dx.doi.org/10.1371/journal.pone.0112765

Ejemplares similares

Polymorphisms in CLDN1 are associated with age and differentiation of triple-negative breast cancer patients
por: Hu, Aimin, et al.
Publicado: (2019)

CLDN1 Sensitizes Triple-Negative Breast Cancer Cells to Chemotherapy
por: Lemesle, Marine, et al.
Publicado: (2022)

Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer
por: Fan, Ying, et al.
Publicado: (2015)

Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC)
por: Ma, Fei, et al.
Publicado: (2017)

CD44(+)/CD24(−) phenotype predicts a poor prognosis in triple-negative breast cancer
por: Wang, Hui, et al.
Publicado: (2017)

Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis
por: Zhang, Jingyi, et al.
Publicado: (2020)

SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer
por: Zhu, Anjie, et al.
Publicado: (2016)

Nestin expression associates with poor prognosis and triple negative phenotype in locally advanced (T4) breast cancer
por: Piras, F., et al.
Publicado: (2011)

Carboxypeptidase A4 accumulation is associated with an aggressive phenotype and poor prognosis in triple-negative breast cancer
por: Handa, Tadashi, et al.
Publicado: (2019)

Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis
por: Shin, Hee-Chul, et al.
Publicado: (2016)

CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer
por: Zhao, Zi-Ming, et al.
Publicado: (2019)

Comment to “Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis”
por: Altundag, Kadri
Publicado: (2016)

Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer
por: Qiu, Jingdan, et al.
Publicado: (2016)

Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients
por: Peng, Wei, et al.
Publicado: (2022)

Expression of RUNX1 Correlates with Poor Patient Prognosis in Triple Negative Breast Cancer
por: Ferrari, Nicola, et al.
Publicado: (2014)

Accumulation of p62 is associated with poor prognosis in patients with triple-negative breast cancer
por: Luo, Rong-Zhen, et al.
Publicado: (2013)

Ki67 as a predictor of poor prognosis in patients with triple-negative breast cancer
por: LI, HAITAO, et al.
Publicado: (2015)

MAT2B expression correlates with poor prognosis in triple-negative breast cancer
por: Xu, Jin, et al.
Publicado: (2019)

circUSP42 Is Downregulated in Triple-Negative Breast Cancer and Associated With Poor Prognosis
por: Yu, Jinling, et al.
Publicado: (2020)

Low KIBRA Expression Is Associated with Poor Prognosis in Patients with Triple-Negative Breast Cancer
por: Kim, So-Woon, et al.
Publicado: (2021)

Down-regulated FST expression is involved in the poor prognosis of triple-negative breast cancer
por: Liu, Sainan, et al.
Publicado: (2021)

Integrated bioinformatic analysis of potential biomarkers of poor prognosis in triple-negative breast cancer
por: Bissanum, Rassanee, et al.
Publicado: (2022)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer
por: Han, Yiqun, et al.
Publicado: (2023)

Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer
por: Cheng, Guangcun, et al.
Publicado: (2016)

Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma
por: Li, Jing-ping, et al.
Publicado: (2019)

Polymorphisms in AURKA and AURKB are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy
por: Liao, Yuqian, et al.
Publicado: (2018)

ID2 predicts poor prognosis in breast cancer, especially in triple-negative breast cancer, and inhibits E-cadherin expression
por: Li, Kai, et al.
Publicado: (2014)

Impact of Triple-Negative Breast Cancer Phenotype on Prognosis in Patients with Stage I Breast Cancer
por: Kim, Jeong Eun, et al.
Publicado: (2012)

CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis
por: Cerqueira, Otto L.D., et al.
Publicado: (2015)

CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2015)

High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer
por: Cao, Zhi-Gang, et al.
Publicado: (2016)

ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer
por: Daulat, Avais M., et al.
Publicado: (2019)

Up-Regulation of RFC3 Promotes Triple Negative Breast Cancer Metastasis and is Associated With Poor Prognosis Via EMT
por: He, Zhen-Yu, et al.
Publicado: (2016)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

Triple-negative breast cancer: current treatment strategies and factors of negative prognosis
por: Baranova, Anna, et al.
Publicado: (2022)

ZGRF1 Is Associated with Poor Prognosis in Triple-Negative Breast Cancer and Promotes Cancer Stemness Based on Bioinformatics
por: Ge, Weiyu, et al.
Publicado: (2020)

There Is No Association between MicroRNA Gene Polymorphisms and Risk of Triple Negative Breast Cancer in a Chinese Han Population
por: Ma, Fei, et al.
Publicado: (2013)

Clinical features and prognosis of triple-negative breast cancer
por: Sanz, M Izquierdo, et al.
Publicado: (2009)

T-cadherin is associated with prognosis in triple-negative breast cancer
por: Kong, De-Di, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n8ovmfh54s6mnkdhi6lkrnbmg3